"Glitazone" Cardiac Effect Might Be Obscured By Placebo - FDA Reviewer
Executive Summary
Possible cardiac effects from "glitazone" class antidiabetic drugs may have been obscured by placebo-controlled clinical trials for Takeda/Lilly's Actos, FDA medical officer Robert Misbin, MD, maintained during the Endocrinologic & Metabolic Drugs Advisory Committee meeting April 23.